Last reviewed · How we verify
Zoledronic Acid Injectable Product
At a glance
| Generic name | Zoledronic Acid Injectable Product |
|---|---|
| Also known as | Aclasta |
| Sponsor | Oslo University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- FARE Augmentation of Proximal Femoral Fractures With CaS/HA and Systemic ZA (PHASE4)
- A Clinical Study on the Safety, Tolerance, and Preliminary Efficacy of γδ-T Cell Injection in the Treatment of Advanced Bladder Cancer
- MAGnesium Effect With ANtiosteoporotic Drugs (PHASE2)
- Denosumab Safety Assessment in Multiple Observational Databases
- Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (Z-AMD) (PHASE2)
- Trochanteric Femur Fracture Operated With Dynamic Hip Screw System (DHS) Augmented With a Biphasic Apatite Sulphate Combined With Systemic or Local Bisphosphonate (NA)
- Denosumab vs Zoledronic Acid and Osteoporotic Compression Fracture (PHASE2, PHASE3)
- Denosumab vs Zoledronate After Lumbar Fusion (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |